A detailed history of Black Rock Inc. transactions in Morpho Sys Ag stock. As of the latest transaction made, Black Rock Inc. holds 1,017,037 shares of MOR stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,017,037
Previous 1,017,852 0.08%
Holding current value
$0
Previous $18.5 Million 0.25%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$17.36 - $19.34 $14,148 - $15,762
-815 Reduced 0.08%
1,017,037 $18.5 Million
Q1 2024

May 10, 2024

BUY
$8.6 - $18.18 $1.32 Million - $2.79 Million
153,252 Added 17.73%
1,017,852 $18.5 Million
Q4 2023

Feb 13, 2024

BUY
$4.55 - $9.9 $3.73 Million - $8.12 Million
820,608 Added 1865.36%
864,600 $8.56 Million
Q3 2023

Nov 13, 2023

BUY
$6.72 - $8.6 $63,114 - $80,771
9,392 Added 27.14%
43,992 $295,000
Q2 2023

Aug 11, 2023

BUY
$3.95 - $7.74 $52,629 - $103,127
13,324 Added 62.62%
34,600 $258,000
Q1 2023

May 12, 2023

SELL
$3.56 - $5.22 $8,672 - $12,715
-2,436 Reduced 10.27%
21,276 $84,000
Q4 2022

Feb 13, 2023

BUY
$3.21 - $5.74 $27,272 - $48,767
8,496 Added 55.84%
23,712 $84,000
Q3 2022

Nov 14, 2022

SELL
$4.14 - $22.13 $178,599 - $954,688
-43,140 Reduced 73.93%
15,216 $77,000
Q2 2022

Aug 12, 2022

SELL
$4.51 - $7.39 $351,013 - $575,163
-77,830 Reduced 57.15%
58,356 $282,000
Q1 2022

May 12, 2022

SELL
$5.87 - $9.73 $342,103 - $567,064
-58,280 Reduced 29.97%
136,186 $923,000
Q4 2021

Feb 10, 2022

SELL
$9.08 - $12.45 $6 Million - $8.23 Million
-660,672 Reduced 77.26%
194,466 $1.83 Million
Q3 2021

Nov 09, 2021

BUY
$11.76 - $19.51 $956,334 - $1.59 Million
81,321 Added 10.51%
855,138 $10.1 Million
Q2 2021

Aug 11, 2021

BUY
$18.95 - $23.95 $14.7 Million - $18.5 Million
773,817 New
773,817 $14.9 Million

Others Institutions Holding MOR

About MorphoSys AG


  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.